Effects of sub-chronic clozapine and haloperidol administration on brain lipid levels

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 4, 2010, Pages 669-673

  Barakauskas, Vilte E ^a   Ypsilanti, Athena R ^a   Barr, Alasdair M ^a   Innis, Sheila M ^a   Honer, William G ^a   Beasley, Clare L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antipsychotic; Cholesterol; Phospholipid; Schizophrenia; Weight

Indexed keywords

CEREBROSIDE; CHOLESTEROL; CLOZAPINE; HALOPERIDOL; LIPID; PHOSPHOLIPID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN MEMBRANE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPID BRAIN LEVEL; LIPID COMPOSITION; MALE; NONHUMAN; RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; BRAIN CHEMISTRY; CHOLESTEROL; CLOZAPINE; HALOPERIDOL; MALE; PHOSPHOLIPIDS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77952672186     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.03.010     Document Type: Article

References (51)

1. Albaugh V.L., Henry C.R., Bello N.T., Hajnal A., Lynch S.L., Halle B., et al. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring) 2006, 14:36-51.
2. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.
3. Andersson C., Hamer R.M., Lawler C.P., Mailman R.B., Lieberman J.A. Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs. Neuropsychopharmacology 2002, 27:143-151.
4. Baptista T., Parada M., Hernandez L. Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved?. Pharmacol Biochem Behav 1987, 27:399-405.
5. Baptista T., Mata A., Teneud L., de Quijada M., Han H.W., Hernández L. Effects of long-term administration of clozapine on body weight and food intake in rats. Pharmacol Biochem Behav 1993, 45:51-54.
6. Barr A.M., Young C.E., Phillips A.G., Honer W.G. Selective effects of typical antipsychotic drugs on SNAP-25 and synaptophysin in the hippocampal trisynaptic pathway. Int J Neuropsychopharmacol 2006, 9:457-463.
7. Baymiller S.P., Ball P., McMahon R.P., Buchanan R.W. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res 2003, 59:49-57.
8. Beasley C.L., Honer W.G., Bergmann K., Falkai P., Lütjohann D., Bayer T.A. Reductions in cholesterol and synaptic markers in association cortex in mood disorders. Bipolar Disord 2005, 7:449-455.
9. Björkhem I., Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 2004, 24:806-815.
10. Cheng C.Y., Hong C.J., Tsai S.J. Effects of subchronic clozapine administration on serum glucose, cholesterol and triglyceride levels, and body weight in male BALB/c mice. Life Sci 2005, 76:2269-2273.
11. Choi S., DiSilvio B., Unangst J., Fernstrom J.D. Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. Life Sci 2007, 81:1024-1030.
12. Dietschy J.M., Turley S.D. Cholesterol metabolism in the brain. Curr Opin Lipidol 2001, 12:105-112.
13. Elder G.A., Cho J.Y., English D.F., Franciosi S., Schmeidler J., Sosa M.A., et al. Elevated plasma cholesterol does not affect brain Abeta in mice lacking the low-density lipoprotein receptor. J Neurochem 2007, 102:1220-1231.
14. Evans D.R., Parikh V.V., Khan M.M., Coussons C., Buckley P.F., Mahadik S.P. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot Essent Fatty Acids 2003, 69:393-399.
15. Fernø J., Raeder M.B., Vik-Mo A.O., Skrede S., Glambek M., Tronstad K.J., et al. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?. Pharmacogenomics J 2005, 5:298-304.
16. Fernø J., Skrede S., Vik-Mo A.O., Håvik B., Steen V.M. Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci 2006, 7:69.
17. Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957, 226:497-509.
18. Gaulin B.D., Markowitz J.S., Caley C.F., Nesbitt L.A., Dufresne R.L. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999, 156:1270-1272.
19. Horrobin D.F., Manku M.S., Hillman H., Iain A., Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatry 1991, 30:795-805.
20. Horrobin D.F., Glen A.I., Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr Res 1994, 13:195-207.
21. Innis S.M., Dyer R.A. Brain astrocyte synthesis of docosahexaenoic acid from n-3 fatty acids is limited at the elongation of docosapentaenoic acid. J Lipid Res 2002, 43:1529-1536.
22. Kale A., Joshi S., Naphade N., Sapkale S., Raju M.S., Pillai A., et al. Opposite changes in predominantly docosahexaenoic acid (DHA) in cerebrospinal fluid and red blood cells from never-medicated first-episode psychotic patients. Schizophr Res 2008, 98:295-301.
23. Kapur S., VanderSpek S.C., Brownlee B.A., Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003, 305:625-631.
24. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 2002, 58:1-10.
25. Knable M.B., Weinberger D.R. Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol 1997, 11:123-131.
26. Komoroski R.A., Pearce J.M., Griffin W.S., Mrak R.E., Omori M., Karson C.N. Phospholipid abnormalities in postmortem schizophrenic brains detected by 31P nuclear magnetic resonance spectroscopy: a preliminary study. Psychiatry Res 2001, 106:171-180.
27. Kyriakopoulos M., Frangou S. Recent diffusion tensor imaging findings in early stages of schizophrenia. Curr Opin Psychiatry 2009, 22:168-176.
28. Levant B., Crane J.F., Carlson S.E. Sub-chronic antipsychotic drug treatment does not alter brain phospholipid fatty acid composition in rats. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:728-732.
29. Lindenmayer J.P., Czobor P., Volavka J., Citrome L., Sheitman B., McEvoy J.P., et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003, 160:290-296.
30. MacDonald M.L., Eaton M.E., Dudman J.T., Konradi C. Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat. Biol Psychiatry 2005, 57:1041-1051.
31. McNamara R.K., Jandacek R., Rider T., Tso P., Hahn C.G., Richtand N.M., et al. Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications. Schizophr Res 2007, 91:37-50.
32. McNamara R.K., Able J.A., Jandacek R., Rider T., Tso P. Chronic risperidone treatment preferentially increases rat erythrocyte and prefrontal cortex omega-3 fatty acid composition: evidence for augmented biosynthesis. Schizophr Res 2009, 107:150-157.
33. Minet-Ringuet J., Even P.C., Lacroix M., Tomé D., de Beaurepaire R. A model for antipsychotic-induced obesity in the male rat. Psychopharmacology (Berl) 2006, 187:447-454.
34. Narayan S., Head S.R., Gilmartin T.J., Dean B., Thomas E.A. Evidence for disruption of sphingolipid metabolism in schizophrenia. J Neurosci Res 2009, 87:278-288.
35. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl 1):1-93.
36. Nuss P., Tessier C., Ferreri F., De Hert M., Peuskens J., Trugnan G., et al. Abnormal transbilayer distribution of phospholipids in red blood cell membranes in schizophrenia. Psychiatry Res 2009, 169:91-96.
37. Paxinos G., Watson C. The rat brain: in stereotaxic coordinates 1986, Academic Press, New York. 2nd ed.
38. Pearce J.M., Komorski R.A., Mrak R.E. Phospholipid composition of postmortem schizophrenic brain by 31P NMR spectroscopy. Magn Reson Med 2009, 61:28-34.
39. Pouzet B., Mow T., Kreilgaard M., Velschow S. Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav 2003, 75:133-140.
40. Procyshyn R.M., Wasan K.M., Thornton A.E., Barr A.M., Chen E.Y., Pomarol-Clotet E., et al. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci 2007, 32:331-338.
41. Reddy R., Keshavan M.S. Phosphorus magnetic resonance spectroscopy: its utility in examining the membrane hypothesis of schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2003, 69:401-405.
42. Rettenbacher M.A., Ebenbichler C., Hofer A., Kemmler G., Baumgartner S., Edlinger M., et al. Early changes of plasma lipids during treatment with atypical antipsychotics. Int Clin Psychopharmacol 2006, 21:369-372.
43. Rolsten C., Claghorn J., Samorajski T. Long-term treatment with clozapine on aging mice. Life Sci 1979, 25:865-872.
44. Schmitt A., Wilczek K., Blennow K., Maras A., Jatzko A., Petroianu G., et al. Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biol Psychiatry 2004, 56:41-45.
45. Schwarz E., Prabakaran S., Whitfield P., Major H., Leweke F.M., Koethe D., et al. High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res 2008, 7:4266-4277.
46. Spivak B., Roitman S., Vered Y., Mester R., Graff E., Talmon Y., et al. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol 1998, 21:245-250.
47. Tschoner A., Engl J., Rettenbacher M., Edlinger M., Kaser S., Tatarczyk T., et al. Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study. Pharmacopsychiatry 2009, 42:29-34.
48. Vik-Mo A.O., Fernø J., Skrede S., Steen V.M. Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells. BMC Pharmacol 2009, 9:10.
49. Wirshing D.A., Boyd J.A., Meng L.R., Ballon J.S., Marder S.R., Wirshing W.C. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002, 63:856-865.
50. Wu R.R., Zhao J.P., Liu Z.N., Zhai J.G., Guo X.F., Guo W.B., et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) 2006, 186:572-578.
51. Yao J.K., Leonard S., Reddy R.D. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res 2000, 42:7-17.